DEVELOPMENT PIPELINE

A strong and diversified pipeline


Camurus’ clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

 

DEVELOPMENT PIPELINE

A strong and diversified pipeline


Camurus’ clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

Pharmaceuticals

CAM2038 q1w Opioid dependence
Registration

CAM2038 q4w Opioid dependence
Registration

CAM2038 q1w Chronic pain
Phase 3

CAM2038 q4w Chronic pain
Phase 3

CAM2029 Neuroendocrine tumors
Phase 1-2

CAM2029 Acromegaly
Phase 1-2

CAM2032 Prostate cancer
Phase 1-2

CAM2047 CINV¹
Phase 1-2

CAM2048/2058 Postoperative pain & PONV²
Phase 1-2

CAM2043 PAH³
Phase 1-2

CAM4071 Undisclosed indication
Phase 1-2

CAM4072 Genetic obesity
Phase 1-2

1) Chemotherapy induced nausea and vomiting, 2) Postoperative nausea and vomiting. 3) Pulmonary arterial hypertension.

Medical device

episil® Oral mucositis
Market

 

CAM2038 opioid dependence

Transforming opioid dependence treatment


Opioid dependence is serious, chronic, relapsing disease. It is a growing global health problem and the largest burden to society of all drugs. Medication assisted treatment (MAT) with daily buprenorphine and methadone is considered standard of care and effective, but is also associated with limitations such as poor treatment adherence, misuse and diversion.

CAM2038 opioid dependence

Transforming opioid dependence treatment


Opioid dependence is serious, chronic, relapsing disease. It is a growing global health problem and the largest burden to society of all drugs. Medication assisted treatment (MAT) with daily buprenorphine and methadone is considered standard of care and effective, but is also associated with limitations such as poor treatment adherence, misuse and diversion.


CAM2038 includes two long-acting subcutaneous buprenorphine investigational products for treatment of opioid dependence. The product candidates are based on Camurus’ proprietary FluidCrystal® injection depot technology and are intended for either weekly (q1w) or monthly (q4w) administration, each in multiple doses to allow individualized treatment of patients with opioid dependence. CAM2038 has the potential to free patients from the burden and stigma associated with the daily, often supervised, distribution and administration of medication.

The investigational products will be provided in prefilled syringes with thin needles, designed for convenient administration by healthcare personnel to ensure proper delivery and treatment compliance, and to minimize the risks of diversion, abuse, misuse, and accidental pediatric exposure. By reduced dosing frequency and thereby costs of treatment under supervision, as well as by improved treatment compliance, CAM2038 also has the potential to generate substantial savings for healthcare and society.

CAM2038 – Key target attributes
• Improved treatment adherence
• Reduced frequency of administrations – from 365 times to 12 times per year
• Minimized risk of diversion and misuse
• Eliminates risk of accidental pediatric exposure
• Flexible dosing and adjustable duration allow individualized therapy in all treatment phases
• Blocks the effects of illicit opioids

 
 

CAM2029 growth hormone disorders

Improving treatment for patients with acromegaly and NET


Somatostatin analogues are the mainstay of medical therapy for patients with acromegaly, and for the effective symptom control in patients with neuroendocrine tumors (NET).

CAM2029 growth hormone disorders

Improved treatment for patients with acromegaly and NET

Somatostatin analogues are the mainstay of medical therapy for patients with acromegaly, and for the effective symptom control in patients with neuroendocrine tumors (NET).


CAM2029 is developed by Novartis, with support from Camurus, for the treatment of acromegaly and neuroendocrine tumors. The product candidate offers important potential advantages over current marketed products, including easy administration, significantly increased bioavailability, and potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects.

CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus’ proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients’ themselves.

CAM2029 – Key target attributes
• Subcutaneous long-acting octreotide
• Fast onset and one month duration of therapeutic plasma-levels
• Provided ready-for-use in prefilled syringes for easy self-administration
• Compatible with autoinjectors
• High bioavailability – 500% higher than Sandostatin® LAR®, with potential for better treatment effects in some patients

 
 

CAM2038 chronic pain

Round-the-clock relief from chronic pain


Chronic pain is a global health problem, causing deterioration in general health, reduced quality of life, decreased work capacity and dependence and misuse of strong opioids.

CAM2038 chronic pain

Round-the-clock relief from chronic pain

Chronic pain is a global health problem, causing deterioration in general health, reduced quality of life, decreased work capacity and dependence and misuse of strong opioids.


CAM2038 includes two long-acting subcutaneous buprenorphine investigational products for treatment of chronic pain. The product candidates are based on Camurus’ proprietary FluidCrystal® injection depot technology and are intended for either weekly (q1w) or monthly (q4w) administration, each in multiple doses, to allow individualized treatment of patients with chronic pain.

CAM2038
is aimed for providing round-the-clock pain relief, while decreasing the risks of respiratory depression and fatal overdoses associated with full µ-opioid agonists, such as morphine, oxycodone and fentanyl. The properties of CAM2038 are considered to conform to the targeted properties and to the guidelines and recommendations for treatments of chronic pain, i.e. the combination of long lasting efficacious analgesia with a reduced risk of misuse, abuse and illicit diversion.

CAM2038 – Key target attributes
• Round-the-clock pain relief
• Dose-proportional long-term buprenorphine exposure
• Improved treatment adherence
• Reduced number of administrations
• Reduced risk of misuse, abuse and diversion
• Reduced risk of overdose compared with full µ-opioid receptor agonists
• Classified as Schedule 3 drug by the US DEA, with moderate to low risk of dependence

 
 

CAM2032 prostate cancer

Easy and convenient long-acting treatment of prostate cancer


Hormone therapies for prostate cancer using gonadotropin-releasing hormone agonists such as leuprolide, are established therapies aimed at reducing the level of testosterone and thereby impeding the growth of cancer cells.

CAM2032 prostate cancer

Easy and convenient long-acting treatment of prostate cancer

Hormone therapies for prostate cancer using gonadotropin-releasing hormone agonists such as leuprolide, are established therapies aimed at reducing the level of testosterone and thereby impeding the growth of cancer cells.


CAM2032 is a long-acting subcutaneous leuprolide investigational product for treatment of prostate cancer. Additional potential indications for CAM2032 include precocious puberty, gender identity disorders, and endometriosis. The product candidate is based on Camurus’ FluidCrystal® injection depot technology and will be provided as a prefilled syringe requiring no reconstitution or conditioning. CAM2032 is being developed for easy subcutaneous injection by patients themselves in the form of a small volume injection with a duration of one month.

CAM2032 – Key target attributes
• Convenient self-administration
• Long-acting duration
• Small injection volume and thin injection needle (27G)
• Compatible with autoinjectors
• Manufacturing by standard processes

 

episil® oral liquid

Effective oral pain relief


Oral mucositis is a painful inflammation and ulceration of the oral mucosa. It is a common and painful side effect of radiotherapy and chemotherapy.

 

episil® oral liquid

Effective oral pain relief

Oral mucositis is a painful inflammation and ulceration of the oral mucosa. It is a common and painful side effect of radiotherapy and chemotherapy.


episil® oral liquid is a medical device for treatment of inflammatory and painful conditions in the oral cavity. The product provides fast pain relief and protection of sore and inflamed mucosal surfaces, as well as severe inflammation caused by e.g. oral mucositis, a common and serious side effect of cancer treatment. In contact with the buccal membrane, episil® transforms into a thin protective layer of gel, offering effective pain relief for up to 8 hours. episil® oral liquid is based on Camurus’ FluidCrystal® topical bioadhesive technology.

For more information, see www.episil.net

 

Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Sölvegatan 41 A. 223 62 Lund, Sweden.
Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email Addresses General enquiries: info@camurus.com
Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations ir@camurus.com